Search the Newsreel

Can Trisura (TSX) Stronger Profit Boost the TSX Composite Index?

How Investors Are Reacting To Trisura Group (TSX:TSU) Stronger Q2 Earnings And EPS Growth

Trisul (TRIS3): Resultados sólidos sustentados pela recuperação das margens

Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?

According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded …

Viatris (VTRS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Markets - Bill Szablewski TAKEAWAYS Revenue -- …

Tristate Board Sets August Meeting to Approve Interim Results and Consider Dividend

Viatris Inc. stock falls Wednesday, underperforms market

Viatris Inc. (VTRS) shares fell by 1.11% on Wednesday, closing at $16.10, underperforming the broader market. The S&P 500 Index saw a gain of 0.26%, while the Dow Jones Industrial Average slightly declined by 0.04%. Viatris Inc. is now trading 12.45% below its 52-week …

Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc

Davis Selected Advisers has reported a beneficial ownership of 75,232,254 shares, representing a 6.5% stake in Viatris Inc. The firm holds sole voting power over 72,567,897 shares and sole dispositive power over all 75,232,254 shares. This disclosure, filed as a Schedule 13G/A, indicates Davis …

Trisura Group (TSX:TSU): Could Strong Results Unlock More Value?

ETFs Investing in Viatris, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Viatris, Inc. (VTRS) stocks, sorted by market value. It details various ETFs, including their issuer, management style, focus, expense ratio, assets under management (AUM), and 3-year NAV total return. The ETFs …

Viatris Inc. (VTRS) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Viatris Inc. (VTRS) stock, including its current price, dividend information, and a collection of recent news articles. The news highlights Viatris's Q2 earnings performance, strategic moves like selling Tyrvaya, and analyst insights on its valuation …

VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook

VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year's revenue to be around $14.75 …

Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run

Viatris (VTRS) stock has seen a 76.1% gain over the past year, yet remains undervalued according to various valuation checks, trading at a discount to sales compared to its industry peers. The recent FDA approval for Gwyn Lo contraceptive patch and the planned sale …

Harrow adds TYRVAYA's global rights to dry eye portfolio

Harrow is expanding its dry eye product portfolio by acquiring the global rights to TYRVAYA (varenicline solution) nasal spray from Viatris, Inc. This FDA-approved nasal spray, indicated for dry eye disease, was originally developed by Oyster Point Pharma. The deal involves a $30 million …

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash

Theravance Biopharma reported its Q2 2026 financial results, including $20.7 million in revenue from its Viatris collaboration and a GAAP net loss of $5.9 million, with $387.7 million in cash and marketable securities. The company highlighted strong YUPELRI performance, a pending acquisition by Zymeworks, …

Trisura Group Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Warum Viatris (VTRS) nach der Anhebung der Prognose und dem Abschluss eines Aktienrückkaufs im Wert von 1,15 Milliarden US-Dollar um 6,4 % nachgibt

Why Viatris (VTRS) Is Down 6.4% After Boosting Guidance And Completing A $1.15 Billion Buyback

Viatris Inc. recently reported higher Q2 and year-to-date revenues, returned to net income, raised its full-year 2026 revenue guidance to US$14.75 billion, and completed a US$1.15 billion share repurchase program. Despite these positive developments, including a new FDA-approved contraceptive patch and reaffirmed dividend, the …

Trisura Group Q2 Earnings Call Highlights

Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program

In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. …

Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be …

Viatris (VTRS) Raises 2026 Guidance, Is The 11% Gap Below Fair Value Enough?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Viatris raises 2026 guidance alongside completed buyback and fresh product approval Viatris (VTRS) has given investors a busy early August, pairing raised 2026 revenue guidance …

Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest research on Viatris centers on a revised price target of US$22 per share and what that figure implies for investors following …

TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins

TriSalus Life Sciences (TLSI) stock surged 15.2% despite the company reporting deeper losses in Q2 2026, with a net loss of US$9.2m and an adjusted EBITDA loss of US$7.1m. While revenue remained flat at US$11.4m, the gross margin improved to 86.8%, indicating strong unit …

Securities Fraud Investigation Into TriSalus Life Sciences Inc

Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into TriSalus Life Sciences Inc. (NASDAQ: TLSI) on behalf of investors who lost money. The investigation follows a significant drop in TriSalus's stock price after the company reported lower-than-expected Q1 revenues and …

Viatris (VTRS) Stock Looks Stuck Between Higher Guidance And Wider Losses

Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW

This page provides financial information for TriSalus Life Sciences, Inc. (NASDAQ: TLSIW), focusing on its price-to-earnings forward ratio. The content indicates that the market was closed with no trades at the time of viewing, and includes copyright information from FactSet, American Bankers Association, and …

TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Expectations

TriSalus Life Sciences (NASDAQ:TLSI) announced its quarterly earnings, reporting a loss of $0.16 per share, which met analyst expectations, while revenue exceeded estimates at $11.41 million. The company's gross margin improved to 86.8%, and management reiterated its 2026 revenue guidance of $54 million to …

TriSalus Life Sciences earnings missed by $0.01, revenue topped estimates

TriSalus Life Sciences (NASDAQ: TLSI) reported second-quarter EPS that missed analyst estimates by $0.01, coming in at $-0.160. However, the company's revenue for the quarter exceeded expectations, reaching $11.41 million against a consensus estimate of $10.79 million. Despite the EPS miss, TriSalus Life Sciences' …

TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Viatris’ high-range grind stands out in a generic-drug group short on Trend Signals

VTRS finished the week at $17.56, just 2.8% below its 52-week high, with an active 49-week trend backdrop but only baseline volume confirmation.

Viatris Earnings: Good Performance in Key Regions and Outlook Increase Make for a Solid Quarter

Viatris reported a strong second quarter with 5% revenue growth and 11% adjusted earnings per share growth, both surpassing FactSet consensus estimates. The company also raised its EPS guidance by 5% at the midpoint, despite shares trading down 3% post-announcement. This performance highlights solid …

Trisura Group Q2 2026 Earnings Call Transcript